DMARDs Lower Dementia Risk in Rheumatoid Arthritis Save
UK researchers have analyzed rheumatoid arthritis (RA) patients from the UK Clinical Practice Research Database and shown that chronic conventional DMARD (cDMARD) use was associated with 40% lower risk of dementia (nearly 50% with methotrexate use).
They compared 3876 cDMARD users to 1938 nonusers among incident RA and found a reduced risk of dementia (hazard ratio: 0.60; 95% confidence interval: 0.42-0.85). The effect was strongest in methotrexate users (hazard ratio: 0.52; 95% confidence interval; 0.34-0.82).
These results suggest a new potential therapeutic role for DMARDs and the possible contribution of inflammation on dementia.